✦ LIBER ✦

Unresectable non-small cell lung cancer (NSCLC) as a target for clinical trials of AG3340, a selective inhibitor of matrix metalloproteases (MMPs), in combination with standard chemotherapies

✍ Scribed by M. Collier; F. Shepherd; M. Keller; G. Michelson; L. Paradiso; N. Clendeninn

Book ID: 117667969
Publisher: Elsevier Science
Year: 1999
Tongue: English
Weight: 322 KB
Volume: 35
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(99)81430-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II clinical trial of celecoxib c

A phase II clinical trial of celecoxib combined with platinum-based regimen as first-line chemotherapy for advanced non-small cell lung cancer patients with cyclooxygenase-2 positive expression

✍ Jun Zhao; Zhi-jie Wang; Jian-chun Duan; Qing-zhi Guo; Hua Bai; Lu Yang; Tong-ton 📂 Article 📅 2009 🏛 Chinese Anti-Cancer Association 🌐 English ⚖ 521 KB

A phase II study of induction chemothera

A phase II study of induction chemotherapy (Ind CT) with CPT-11 and cisplatin followed by thoracic radiation (TRT) combined with weekly CPT-11 in patients with unresectable stage III non-small-cell lung cancer (NSCLC): A Japan Clinical Oncology (JCOG) 9706 Trial

✍ Takifuji, N; Negoro, S; Fukuoka, M; Kawahara, M; Ishizuka, N; Saijo, N; Shimoyam 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 114 KB

9000 ORAL Epidermal Growth Factor Recept

9000 ORAL Epidermal Growth Factor Receptor (EGFR) Expression as a Predictive Biomarker of Survival in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Receiving First-Line Therapy With Cetuximab Combined With Chemotherapy in the FLEX Trial

✍ O'Bvrne, K.; Paz-Ares, L.; Pereira, J.R.; von Pawel, J.; Ramlau, R.; Störkel, S. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 43 KB

Motexafin Gadolinium (MGd) is Active as

Motexafin Gadolinium (MGd) is Active as a Single Agent and in Combination with Pemetrexed and Docetaxel in Advanced Non–Small-Cell Lung Cancer (NSCLC) Patients who Failed Platinum-Based Chemotherapy: Early Results of 3 Phase II Trials

✍ R.B. Natale; G. Nicholas; K. Pandya; M. Edelman; S.C. Phan; M.F. Renschler 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 443 KB

A phase I/randomized phase II, non-compa

A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)

✍ Roger B. Cohen; Corey J. Langer; George Rajan Simon; Peter David Eisenberg; John 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 387 KB

53 POSTER A phase II, multicenter, rando

53 POSTER A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab (Avastin®) in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride (Tarceva®) compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer

✍ R. Herbst; V. O'Neill; L. Fehrenbacher; C. Belani; P. Bonomi; L. Hart; O. Melnyk 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 59 KB